Contract HHSO100201500013C

Regeneron Pharmaceuticals Inc · Department Of Health And Human Services · September 1, 2015

Firm Fixed PriceFull & Open CompetitionNAICS 541711

Regeneron Pharmaceuticals Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on September 1, 2015 for $33.14 million of work in research and development in biotechnology. It was awarded under full and open competition. The contract has been modified 11 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on July 23, 2024.

Obligated to date
$33.14M
$33,135,560
Potential value
$44.44M
if all options exercised
Modifications
11
Latest July 23, 2024

Contract details

PIID
HHSO100201500013C
Award type
Pricing
Firm Fixed Price
Set-aside
No Set Aside Used.
Competition
Full And Open Competition
NAICS
541711 · Research And Development In Biotechnology
Product / service
Health R&D Services; Health Care Services; Experimental Development
First action
September 1, 2015
Latest action
July 23, 2024

Description

DE-OBLIGATE FISCAL YEAR 2024 CANCELING FUNDS.

Modification timeline

  • July 23, 2024
    Mod P00011
    $-1.44M
  • August 8, 2023
    Mod P00010
    REVISE THE CONTRACTING OFFICER REPRESENTATIVE, REVISE SECTION B ARTICLE B.4. ADVANCE UNDERSTANDINGS, REVISE SECTION G ARTICLE G.5. INVOICE DELIVERABLE TABLE OPT
    $0
  • September 23, 2022
    Mod P00009
    REGENERON- ADD HHSAR CLAUSE AT 352.232-71, ELECTRONIC SUBMISSION OF PAYMENT REQUESTS.
    $0
  • April 13, 2021
    Mod P00008
    REGENERON-ANTI-EBOLA ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT
    $0
  • November 6, 2018
    Mod 7
    REGENERON-ANTI-EBOLA ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT IGF::OT::IGF
    $0
  • October 24, 2017
    Mod 6
    REGENERON-ANTI-EBOLA ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT IGF::OT::IGF
    $0
  • May 31, 2017
    Mod 5
    REGENERON-ANTI-EBOLA ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT IGF::OT::IGF
    $15.09M
  • May 23, 2017
    Mod 4
    IGF::OT::IGF REGENERON-ANTI-EBOLA ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT
    $0
  • October 25, 2016
    Mod 3
    REGENERON-ANTI-EBOLA ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT IGF::OT::IGF
    $0
  • August 9, 2016
    Mod 2
    REGENERON-ANTI-EBOLA ANTIBODY THERAPEUTICS PROGRAM DEVELOPMENT IGF::OT::IGF
    $0

Similar contracts

RecipientAgencyDateObligated
University Of IllinoisDepartment Of Health And Human ServicesMarch 26, 2026$2.27M
Battelle Memorial InstituteDepartment Of Health And Human ServicesMarch 25, 2026$9.65M
University Of Texas Medical Branch At GalvestonDepartment Of Health And Human ServicesMarch 23, 2026$1.61M
Regeneron Pharmaceuticals IncDepartment Of Health And Human ServicesMarch 19, 2026$8.60M
Battelle Memorial InstituteDepartment Of Health And Human ServicesMarch 17, 2026$2.23M
Battelle Memorial InstituteDepartment Of Health And Human ServicesMarch 17, 2026$2.22M

Top contractors in NAICS 541711

Lifetime obligated dollars across all federal contracts in this NAICS code.

Track this on BesaGov

Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.

✓ You’re on the list. We’ll never spam you.

Helpful guides

Continue learning

See all guides →
More on BesaGov

Keep researching

Track this contract, set alerts on similar opportunities, and build proposal pipelines on BesaGov.
Sign up free

Frequently asked questions

What is contract HHSO100201500013C?

Contract HHSO100201500013C is a federal contract awarded to Regeneron Pharmaceuticals Inc by Department Of Health And Human Services on September 1, 2015 for $33.14 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY. It has been modified 11 times since the base award.

Who won contract HHSO100201500013C?

Regeneron Pharmaceuticals Inc won contract HHSO100201500013C from Department Of Health And Human Services.

How much is contract HHSO100201500013C worth?

Contract HHSO100201500013C has obligated $33.14 million to date, with a total potential value of $44.44 million if all options are exercised.